DOCSLIB.ORG

Comprehensive PREFERRED DRUG LIST

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive PREFERRED DRUG LIST Comprehensive PREFERRED DRUG LIST WSI PAGE 1 LAST UPDATED 02/2018 LEGEND TYPE DESCRIPTION There is a limit on the amount of drug covered per prescription, or QL Quantity Limit within a specific time frame. PA Prior Authorization Prior Authorization required before prescription can be filled. MDD Max Daily Dose A limit on the number of times the drug can be taken per day. C Custom This drug has unique restrictions. PAGE 2 LAST UPDATED 02/2018 LIST OF COVERED OVER-THE-COUNTER MEDICATIONS BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS ANALGESICS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ibuprofen tab 200 mg generic adult aspirin ec low strength 81 mg tab dr generic adult aspirin regimen 81 mg tab dr generic advil junior strength 100 mg chew tab generic ALKA-SELTZER EXTRA STRENGTH 500 MG EFFER TAB BRAND C Non-Formulary Drug aspirin effervescent anacin 81 mg tab dr generic ASCRIPTIN MS 500-33-33-237 MG TAB BRAND aspirin buffered (al hydrox-mg hydrox-ca carb) aspir-81 81 mg tab dr generic aspir-low 81 mg tab dr generic aspirin 300 mg suppos generic aspirin 81 mg tab generic aspirin 81 mg tab dr generic aspirin adult low dose 81 mg tab dr generic aspirin adult low strength 81 mg tab dr generic aspirin ec 81 mg tab dr generic aspirin ec adult low strength 81 mg tab dr generic aspirin ec lo-dose 81 mg tab dr generic aspirin ec low dose 81 mg tab dr generic aspirin ec low strength 81 mg tab dr generic aspirin low dose 81 mg tab dr generic aspirin regimen low dose adult 81 mg tab dr generic backache relief extra strength 580 mg tab generic C Non-Formulary Drug bayer aspirin ec low dose 81 mg tab dr generic bayer low dose 81 mg tab dr generic PAGE 3 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS bayer low strength 81 mg tab dr generic BC FAST PAIN RELIEF ARTHRITIS 742-222-38 MG PACKET BRAND C Non-Formulary Drug aspirin-salicylamide-caffeine child ibuprofen 100 mg/5ml suspension generic childrens ibuprofen 100 100 mg/5ml suspension generic childrens ibuprofen 100 mg/5ml suspension generic childrens medi-profen 100 mg/5ml suspension generic childs ibuprofen 100 mg/5ml suspension generic cope 400-32 mg tab generic C Non-Formulary Drug cvs aspirin 81 mg tab dr generic cvs aspirin adult low strength 81 mg tab dr generic cvs aspirin ec 81 mg tab dr generic cvs aspirin low dose 81 mg tab dr generic cvs aspirin low strength 81 mg tab dr generic cvs childrens ibuprofen 100 mg/5ml suspension generic cvs effervescent antacid 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic cvs ibuprofen childrens 100 mg/5ml suspension generic ibuprofen tab 200 mg generic cvs ibuprofen junior strength 100 mg chew tab generic doans extra strength 580 mg tab generic C Non-Formulary Drug ibuprofen tab 200 mg generic ec-81 aspirin 81 mg tab dr generic ecotrin low strength 81 mg tab dr generic effervescent antacid/pain rel 325-1000-1916 mg effer tab generic C Non-Formulary Drug effervescent pain relief 325 mg effer tab generic C Non-Formulary Drug effervescent pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug eq adult aspirin low strength 81 mg tab dr generic PAGE 4 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS eq antacid & pain relief 325 mg effer tab generic C Non-Formulary Drug eq aspirin adult low dose 81 mg tab dr generic eq aspirin low dose 81 mg tab dr generic eq childrens ibuprofen 100 mg/5ml suspension generic eq effervescent pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic eq ibuprofen junior 100 mg chew tab generic eql adult aspirin low strength 81 mg tab dr generic eql antacid/pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug eql aspirin ec 81 mg tab dr generic eql aspirin low dose 81 mg tab dr generic eql childrens ibuprofen 100 mg/5ml suspension generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic eql ibuprofen junior strength 100 mg chew tab generic ibuprofen tab 200 mg generic gnp adult aspirin low strength 81 mg tab dr generic gnp aspirin 81 mg tab dr generic gnp aspirin low dose 81 mg tab dr generic gnp childrens ibuprofen 100 mg/5ml suspension generic gnp effervescent antacid/pain 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic gnp ibuprofen junior strength 100 mg chew tab generic goodsense antacid/pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug goodsense aspirin low dose 81 mg tab dr generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic PAGE 5 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS goodsense ibuprofen childrens 100 mg/5ml suspension generic goodsense ibuprofen junior st 100 mg chew tab generic GOODYS EXTRA STRENGTH 520-260-32.5 MG PACKET BRAND C Non-Formulary Drug aspirin-acetaminophen-caffeine h-e-b aspirin 81 mg tab dr generic halfprin 81 mg tab dr generic hm aspirin ec low dose 81 mg tab dr generic hm ibuprofen 100 mg chew tab generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic hm ibuprofen childrens 100 mg/5ml suspension generic ibuprofen tab 200 mg generic hyvee ibuprofen childrens 100 mg/5ml suspension generic ibuprofen tab 200 mg generic ibuprofen tab 200 mg generic ibuprofen 100 junior strength 100 mg chew tab generic ibuprofen 100 mg/5ml suspension generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic ibuprofen childrens 100 mg/5ml suspension generic ibuprofen junior strength 100 mg chew tab generic kls aspirin low dose 81 mg tab dr generic ibuprofen tab 200 mg generic ibuprofen tab 200 mg generic kp aspirin 81 mg tab dr generic ibuprofen cap 200 mg generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic medi-seltzer 325 mg effer tab generic C Non-Formulary Drug ibuprofen tab 200 mg generic PAGE 6 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS ibuprofen cap 200 mg generic miniprin low dose 81 mg tab dr generic ibuprofen tab 200 mg generic neutralin 325-1000-1916 mg effer tab generic C Non-Formulary Drug p-a-c 400-32 mg tab generic C Non-Formulary Drug ibuprofen tab 200 mg generic px childrens profen ib 100 mg/5ml suspension generic px effervescent 325-1000-1916 mg effer tab generic C Non-Formulary Drug px enteric aspirin 81 mg tab dr generic ibuprofen tab 200 mg generic px ibuprofen junior strength 100 mg chew tab generic qc aspirin low dose 81 mg tab dr generic qc childrens ibuprofen 100 mg/5ml suspension generic qc effervescent antacid/pain 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic ibuprofen tab 200 mg generic ra antacid pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug ra aspirin adult low strength 81 mg tab dr generic ra aspirin ec 81 mg tab dr generic ra aspirin ec adult low st 81 mg tab dr generic ra backache relief 580 mg tab generic C Non-Formulary Drug ra ibuprofen 100 mg/5ml suspension generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic ra ibuprofen childrens 100 mg/5ml suspension generic ra ibuprofen junior strength 100 mg chew tab generic sb aspirin 81 mg tab dr generic sb aspirin adult low strength 81 mg tab dr generic PAGE 7 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS sb childrens ibuprofen 100 mg/5ml suspension generic sb effervescent pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen tab 200 mg generic sb low dose asa ec 81 mg tab dr generic sm aspirin adult low strength 81 mg tab dr generic sm aspirin ec low strength 81 mg tab dr generic sm aspirin low dose 81 mg tab dr generic sm childrens ibuprofen 100 mg/5ml suspension generic sm effervescent pain relief 325-1000-1916 mg effer tab generic C Non-Formulary Drug ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic sm ibuprofen ib 100 mg chew tab generic ibuprofen tab 200 mg generic st joseph aspirin 81 mg tab dr generic tgt aspirin 81 mg tab dr generic tgt aspirin low dose 81 mg tab dr generic tgt childrens ibuprofen 100 mg/5ml suspension generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic tgt ibuprofen childrens 100 mg/5ml suspension generic tgt ibuprofen junior strength 100 mg chew tab generic th aspirin low dose 81 mg tab dr generic ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic VANQUISH 227-194-33 MG TAB BRAND C Non-Formulary Drug aspirin-acetaminophen-caffeine (buffered) ibuprofen cap 200 mg generic ibuprofen tab 200 mg generic zee-zeltzer 325-1000-1916 mg tbef generic C Non-Formulary Drug PAGE 8 LAST UPDATED 02/2018 BRAND/GENE PRODUCT DESCRIPTION RIC LIMITS & RESTRICTIONS ANESTHETICS LOCAL ANESTHETICS anesthetic maximum strength 20 % gel generic PA benz-o-sthetic 20 % gel generic PA cvs oral anesthetic max str 20 % gel generic PA cvs oral pain reliever 20 % cream generic hurricaine 20 % gel generic PA intense toothache pain relief 20 % gel generic PA orabase maximum strength 20 % gel generic PA oral analgesic max st 20 % gel generic PA oral pain relief max st 20 % gel generic PA orastat maximum strength 20 % gel generic PA ra anesthetic oral 20 % gel generic PA ANTI-ADDICTION/SUBSTANCE ABUSE TREATMENT AGENTS SMOKING CESSATION AGENTS cvs nicotine polacrilex 2 mg gum generic PA cvs nicotine polacrilex 4 mg gum generic cvs nicotine polacrilex 4 mg lozenge generic PA eq nicotine 2 mg gum generic PA eq nicotine 4 mg gum generic eq nicotine 4 mg lozenge generic PA eq nicotine polacrilex 2 mg gum generic PA eq nicotine polacrilex
Load more

Recommended publications
  • Eluxadoline: a Treatment for IBS with Diarrhoea in Adults
    ■ NEW PRODUCT Eluxadoline: a treatment for IBS with diarrhoea in adults STEVE CHAPLIN Eluxadoline (Truberzi) KEY POINTS is an oral mixed opioid- receptor agonist/ ■ Eluxadoline is an opioid-receptor agonist/antagonist with low systemic absorption antagonist licensed for ■ It is licensed for the treatment of irritable bowel syndrome with diarrhoea in the treatment of irritable adults and is recommended by NICE as a second-line agent bowel syndrome with ■ The recommended dosage is 75–100mg orally twice daily diarrhoea in adults. ■ In clinical trials, response rates were 27%–31% with eluxadoline and 19.5% with placebo after 26 weeks’ treatment This article examines its ■ Common adverse effects include constipation, nausea and abdominal pain properties, efficacy in ■ Pancreatitis and sphincter of Oddi spasm were uncommon adverse events clinical trials and side- ■ Treatment with eluxadoline costs £88.20 per month. effects. he initial management of irritable locally within the gastrointestinal tract, Tbowel syndrome (IBS) entails dietary slowing gastrointestinal transit, reducing and lifestyle change and treatment with urgency and improving stool consistency; antispasmodic agents.1 For people with its abuse potential is low. IBS and diarrhoea, loperamide is the anti- Eluxadoline is licensed for the treat- motility agent of first choice, adjusting the ment of IBS with diarrhoea in adults. The dose to achieve optimum stool consist- recommended dosage is 100mg twice ency. If this is unsatisfactory, treatment daily (reduced to 75mg twice daily if with a low-dose tricyclic antidepressant poorly tolerated). Treatment should be should be considered, with an SSRI a initiated at the lower dose in older people further option if this is unsuccessful.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Today's Research Tomorrow's Cure
    2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Building Innovation, Performance and Trust
    Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • 2009 Nhamcs Micro-Data File Documentation Page 1
    2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
    [Show full text]
  • Surveillance Review Proposal PDF 387 KB
    National Institute for Health and Care Excellence Surveillance programme Surveillance proposal consultation document Irritable bowel syndrome NICE guideline CG61 – 8-year surveillance review Background information Guideline issue date: February 2008 3-year review (no update)* 6-year review (yes to update) *Although the 3-year review decision was no update, the findings were subsequently used to pilot the NICE’s rapid update process. Surveillance proposal for consultation We will not update the guideline at this time. Reason for the proposal New evidence We found 105 new studies in a search for randomised controlled trials (RCTs) and systematic reviews published between 01 September 2013 and 18 July 2016. We also considered studies identified by members of the guideline committee who originally worked on this guideline. Evidence identified in previous surveillance 3 years and 6 years after publication of the guideline was also considered. This included 52 studies identified by search. From all sources, 157 studies were considered to be relevant to the guideline. Surveillance proposal consultation document for Irritable bowel syndrome (2008) NICE guideline CG61 1 of 44 This included new evidence that is consistent with current recommendations on: diagnosis of irritable bowel syndrome (IBS) dietary interventions physical activity interventions drug treatments (antispasmodics, laxatives, anti-motility agents and antidepressants) psychotherapy hypnotherapy, biofeedback and relaxation therapy acupuncture and patient information. We also identified new evidence in the following areas that was inconsistent with, or not covered by, current recommendations, but the evidence was not considered to impact on the guideline: ondansetron vitamin D supplementation herbal medicines. We did not find any new evidence on reflexology, psychosocial interventions, or self-help and support groups.
    [Show full text]
  • Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
    ORIGINAL CONTRIBUTIONS 1 see related editorial on page x Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea Brooks D. Cash , MD 1 , Brian E. Lacy , MD, PhD 2 , Philip S. Schoenfeld , MD 3 , Leonard S. Dove , PhD 4 and Paul S. Covington , MD 4 OBJECTIVES: Eluxadoline is a mixed μ -opioid receptor (OR) and κ -OR agonist and δ -OR antagonist, approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D). This analysis evaluated the safety and tolerability of eluxadoline 75 and 100 mg twice daily (BID) in one Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) studies. METHODS: Adults with IBS-D (Rome III criteria) were randomized to placebo or eluxadoline (75 or 100 mg) BID for 12 (IBS-2001), 26 (IBS-3002), or 52 (IBS-3001) weeks. Safety data were pooled. Adverse events (AEs) were assessed, with special focus on opioid-related AEs, including suspected sphincter of Oddi spasm (SOS) events. RESULTS: 2,776 patients were included in the enrolled set; the safety set comprised 2,814 patients, based on FUNCTIONAL GI DISORDERS actual treatments received. The most frequent AEs in the placebo and eluxadoline 75 and 100 mg groups were constipation (2.5, 7.4, and 8.1%, respectively) and nausea (5.0, 8.1, and 7.1%, respectively); discontinuation due to constipation was uncommon (0.3, 1.1, and 1.5%, respectively). Ten SOS events (10/1,839; 0.5%) occurred in eluxadoline-treated patients, manifesting as acute abdominal pain with elevated aminotransferases or lipase, or pancreatitis; all occurred in patients without a gallbladder.
    [Show full text]
  • 2015.09 IBS Drug Class Review.Pdf
    Drug Class Review Agents Indicated in the Treatment of Irritable Bowel Syndrome 56:92 GI Drugs, Miscellaneous Alosetron (Lotronex®) Eluxadoline (Viberzi®) Linaclotide (Linzess®) Lubiprostone (Amitiza®) Tegaserod (Zelnorm®) Final Report September 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Irene Pan, PharmD Candidate 2016 Chelsey Hancock, PharmD Candidate 2016 Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. 1 Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Comparison of the Agents Indicated in the Treatment of IBS ................................. 5 Disease Overview ........................................................................................................................ 6 Table 2. Summary of IBS Treatment Options ........................................................................ 8 Table 3. IBS Disease Staging System .................................................................................... 11 Table 4. Most Current Clinical Practice Guidelines for the Treatment of IBS ..................... 13 Pharmacology ..............................................................................................................................
    [Show full text]